QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.000349v1 66/5/1192    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, X. Articles by Gershengorn, M. C. Search for Related Content PubMed PubMed Citation Articles by Lu, X. Articles by Gershengorn, M. C.

A Model of Inverse Agonist Action at Thyrotropin-Releasing Hormone Receptor Type 1: Role of a Conserved Tryptophan in Helix 6

Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (X.L., W.H., S.W., M.C.G.); and Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York, New York (P.D., R.O.)

A binding pocket for thyrotropin-releasing hormone (TRH) within the transmembrane helices of the TRH receptor type 1 (TRH-R1) has been identified based on experimental evidence and computer simulations. To determine the binding site for a competitive inverse agonist, midazolam, three of the four residues that directly contact TRH and other residues that restrain TRH-R1 in an inactive conformation were screened by mutagenesis and binding assays. We found that two residues that directly contact TRH, Asn-110 in transmembrane helix 3 (3.37) and Arg-306 in transmembrane helix 7 (7.39), were important for midazolam binding but another, Tyr-282 in transmembrane helix 6 (6.51), was not. A highly conserved residue, Trp-279 in transmembrane helix 6 (6.48), which was reported to be critical in stabilizing TRH-R1 in an inactive state but not for TRH binding, was critical for midazolam binding. We used our previous model of the unoccupied TRH-R1 to generate a model of the TRH-R1/midazolam complex. The experimental results and the molecular model of the complex suggest that midazolam binds to TRH-R1 within a transmembrane helical pocket that partially overlaps the TRH binding pocket. This result is consistent with the competitive antagonism of midazolam binding. We suggest that the mechanism of inverse agonism effected by midazolam involves its direct interaction with Trp-279, which contributes to the stabilization of the inactive conformation of TRH-R1.

Address correspondence to: To whom correspondence and reprint requests should be addressed: Marvin C. Gershengorn, Scientific Director, NIDDK, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892-1818. E-mail: marving{at}intra.niddk.nih.gov

This article has been cited by other articles:

				S. Engel, S. Neumann, N. Kaur, V. Monga, R. Jain, J. Northup, and M. C. Gershengorn Low Affinity Analogs of Thyrotropin-releasing Hormone Are Super-agonists J. Biol. Chem., May 12, 2006; 281(19): 13103 - 13109. [Abstract] [Full Text] [PDF]